| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_83399a7eb9343c555da423f8a7a5f590 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate |
2009-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02d4d253ccaf9c689277104a06facebe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22e13fee409790f150e498757b54f011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5e95c6de9b00ff09f964c413e213dd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9f0d597353f140f585aaf2f58d25c07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75956d6d69d94e4c2612eae20ad4b4c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64fb2dc619f4b982009cecaa33631df5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1e6bcc5c822db80a7070ca044840536 |
| publicationDate |
2011-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2340043-A1 |
| titleOfInvention |
Topical composition comprising a combination of at least two penetration enhancing agents |
| abstract |
The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least one of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols, and iso-form alcohols; wherein at least one of the penetration enhancing agents is selected from the group consisting of aliphatic diols and triols; and wherein the components are present in a non-aqueous solvent system. A preferred topical composition comprises the active substance imiquimod and the penetration enhancing agents isopropyl myristate and propylene glycol. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013181084-A1 |
| priorityDate |
2008-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |